Impact of therapy with statins, beta-blockers and angiotensin-converting enzyme inhibitors on plasma myeloperoxidase in patients with coronary artery disease
Authors:
- 5 November 2010
- journal article
- research article
- Published by Springer Nature in Clinical Research in Cardiology
- Vol. 100 (4) , 327-333
Abstract
Purpose The present study investigated whether therapy with statins, beta-blockers and angiotensin-converting enzyme (ACE) inhibitors on admission affects the plasma level of myeloperoxidase (MPO) in patients with coronary artery disease (CAD). Methods This study included a consecutive series of 680 patients with angiographically confirmed CAD: 382 patients with stable CAD, 107 patients with unstable angina and 191 patients with ST-segment elevation acute myocardial infarction. Blood samples for MPO measurement were taken before angiography prior to heparin administration. Results On admission, 316 patients were receiving statins, 432 patients were receiving beta-blockers and 354 patients were receiving ACE inhibitors. MPO level was: 65.5 [48.8–101.6] μg/L among patients on statin therapy versus 86.7 [56.0–159.9] μg/L among patients without statin therapy (P < 0.001); 68.1 [50.1–105.1] μg/L among patients on beta-blocker therapy versus 97.3 [56.0–181.9] μg/L among patients without beta-blocker therapy (P < 0.001) and 65.5 [49.2–102.0] μg/L among patients receiving ACE inhibitors versus 92.0 [56.1–171.1] μg/L among patients not receiving ACE inhibitors on admission (P < 0.001). The MPO-lowering effect of these drugs was observed only in patients with acute coronary syndrome but not in patients with stable CAD. The multivariable analysis, adjusting for cardiovascular risk factors, clinical variables and concomitant therapy identified beta-blockers on admission as an independent correlate of lower MPO levels (P = 0.016). Conclusions In patients with symptomatic CAD, beta-blocker therapy on admission was independently associated with lower levels of plasma MPO. Pre-admission therapy with statins, beta-blockers or ACE inhibitors reduced MPO levels in patients with acute coronary syndromes, but not in patients with stable CAD.Keywords
This publication has 28 references indexed in Scilit:
- Effects of rosuvastatin on myeloperoxidase levels in patients with chronic heart failure: A randomized placebo-controlled studyAtherosclerosis, 2009
- Myeloperoxidase level in patients with stable coronary artery disease and acute coronary syndromesEuropean Journal of Clinical Investigation, 2008
- Myeloperoxidase levels are not associated with carotid atherosclerosis progression in patients with familial hypercholesterolemiaAtherosclerosis, 2007
- Plasma Concentrations of Myeloperoxidase Predict Mortality After Myocardial InfarctionJACC, 2007
- Multiple Biomarker Use for Detection of Adverse Events in Patients Presenting with Symptoms Suggestive of Acute Coronary SyndromeClinical Chemistry, 2007
- National Academy of Clinical Biochemistry Laboratory Medicine Practice Guidelines: Clinical Characteristics and Utilization of Biochemical Markers in Acute Coronary SyndromesClinical Chemistry, 2007
- Effect of statins on the mortality of patients with ischaemic heart disease: population based cohort study with nested case-control analysisHeart, 2005
- Statins downregulate myeloperoxidase gene expression in macrophagesBiochemical and Biophysical Research Communications, 2005
- Angiotensin II inhibition during myocardial ischemia–reperfusion in dogs: effects on leukocyte infiltration, nitric oxide synthase isoenzymes activity and left ventricular ejection fractionInternational Journal of Cardiology, 2005
- Overview of results of randomized clinical trials in heart disease. I. Treatments following myocardial infarction1988